Our recent preclinical study confirmed that epithelial cell adhesion molecule (EpCAM) is a valid target antigen for CAR-T cell therapy and demonstrated that EpCAM-specific CAR-T cells possess significant anti-tumor function against gastric cancer (GC)22. Here, EPCAM is linked to neoplasm.